Treatment of Tuberculosis, 2017
|
|
- Bernice Thompson
- 6 years ago
- Views:
Transcription
1 Treatment of Tuberculosis, 2017 Charles L. Daley, MD National Jewish Health University of Colorado Health Sciences Center
2 Treatment of Tuberculosis Disclosures Advisory Board Horizon, Johnson and Johnson, Otsuka and Spero Investigator Insmed
3 Objectives After participating in this lecture, you should be able to: 1. Describe the objectives of anti tuberculosis therapy 2. Describe the recommended treatment regimens for drug susceptible pulmonary TB 3. Describe the recommended approach to treatment monitoring
4 Outline Approach to treatment decisions in patients with suspected TB? Objectives of Anti tuberculosis Therapy Organization and Supervision of Therapy Recommended Treatment Regimens Treatment of Paucibacillary Disease Monitoring for Treatment Response and Adverse Drug Reactions Can we shorten the duration of therapy?
5 Asian Born Student in her 20 s, PPD+ at college clinic Asymptomatic Erythromycin for mild pneumonia 6 mo. ago in Asia Chest X ray: nodular infiltrate
6 Audience Response Question Which of the following would be the most appropriate next step? A. Collect sputum for culture and wait for results B. Collect sputum for culture and start 4 drug regimen C. Begin isoniazid and rifampin preventive therapy D. Begin treatment for community acquired pneumonia E. Do nothing, her TST result is likely a false positive
7 Factors Affecting Decision to Initiate Treatment Patient Laboratory/ Radiologic Clinical status/ suspicious Public Health Risk for progression Young age (< 2 yo) TB exposure Radiograph cw TB Smear positive, NAAT positive Smear negative, NAAT positive Life threatening disease Symptoms cw TB Alternative diagnosis unlikely High transmission risk Concern for lost to f/u Risk for AE No TB exposure Radiograph not cw TB Smear positive, NAAT negative Smear negative, NAAT negative Stable disease Symptoms not cw TB Alternative diagnosis likely Low transmission risk Favors Treatment Initiation Favors Delayed or no Treatment
8 Objectives Of Anti-tuberculosis Therapy Rapid killing of multiplying bacilli (bactericidal effect) Achievement of relapse-free cure (sterilizing effect) Protection against acquisition of drug resistance INH RIF, PZA INH, RIF, EMB Never treat active TB with a single drug
9 Organization and Supervision of Therapy (2) 1. Do case management interventions improve outcomes compared to curative therapy alone among patients with TB? We suggest using case management interventions (conditional recommendation, low quality of evidence) Studies Patient Education and Counseling Standard Approach Relative Risk Adherence % 29.3% 1.83 ( ) Treatment Completion % 42.0% 1.71 ( )
10 Organization and Supervision of Therapy (2) 2. Does self administered therapy (SAT) have similar outcomes compared to directly observed therapy (DOT) in patients with various forms of TB? We suggest using DOT rather than SAT (conditional recommendation, low quality of evidence) Studies DOT SAT Relative Risk Treatment Success % 73.0% 0.94 ( ) Culture conversion % 81.8% 0.92 ( ) No difference in mortality, treatment completion or relapse
11 Organization and Supervision of Therapy (2) 2. Does self administered therapy (SAT) have similar outcomes compared to directly observed therapy (DOT) in patients with various forms of TB? We suggest using DOT rather than SAT (conditional recommendation, low quality of evidence) Studies DOT SAT Relative Risk Treatment Success % 73.0% 0.94 ( ) Culture conversion % 81.8% 0.92 ( ) No difference in mortality, treatment completion or relapse Population-based studies: reduction in acquisition and transmission of drug-resistant TB (Texas), increased treatment success in HIV infected patients (NYC) reduction in mortality and lost to follow-up (Brazil)
12 Priority Situations for the Use of Directly Observed Therapy Positive sputum smear Treatment failure/relapse Drug resistance HIV infection Previous treatment Intermittent dosing Current or prior substance abuse Previous nonadherence Children/adolescents Mental/emotional/ physical disability Resident at correctional or long-term care facility Homelessness
13 Treatment of Tuberculosis Standard Regimen Isoniazid Rifampin Pyrazinamide Ethambutol Initial Phase Continuation Phase months
14 Duration of Treatment Regimen Duration, mos Treatment Success SM, PAS % INH, SM, PAS % INH, SM (or EMB), PZA 9 95% 2 INH, RIF, SM/ 7 INH, RIF 9 95% 2 INH, RIF, EMB/ 7 INH, RIF 9 95% 2 INH, RIF, EMB, PZA/ 4 INH, RIF 6 95%
15 Recommended Treatment Regimens Daily vs. Intermittent Dosing? 3. Does intermittent dosing in the intensive phase have similar outcomes compared to daily dosing in the intensive phase for treatment of drug susceptible pulmonary TB? Daily rather than intermittent dosing (strong recommendation, moderate quality of evidence) Three times weekly therapy may be considered in patients who are not HIV-infected and at low risk for relapse (non-cavitary and/or smear negative (conditional recommendation, low quality of evidence) Twice weekly therapy after an initial two weeks of daily therapy may be considered for patients who are not HIV-infected and are also at low risk risk of relapse (conditional recommendation/very low quality of evidence)
16 Recommended Treatment Regimens Daily vs. Intermittent Dosing? 4. Does intermittent dosing in the continuation phase have similar outcomes compared to daily dosing in the intensive phase for treatment of drug susceptible pulmonary TB? Daily or three times weekly continuation phase (strong recommendation, moderate quality of evidence) Three times weekly instead of twice weekly therapy if intermittent therapy is used (conditional recommendation, low quality of evidence) Recommend against use of once weekly therapy with rifapentine 600 mg (strong recommendation, high quality of evidence)
17 Relapse Rates By Cavitation and 6 month regimen 2 Month Culture Status Cav+ C2m+ Cav+ C2m Cav C2m+ Cav C2m Daily Daily IP + thrice weekly CP Daily IP + twice weekly CP Thrice weekly Daily IP with Rp in CP Thrice weekly IP with Rp in CP IP intensive phase, CP continuation phase, Rp rifapentine Cav cavitary, C2m 2 month culture status Chang et al, AJRCCM 2006; 174;
18 Preferred Regimens for Newly Initial Continuation Reg Drugs Interval/Dose Drugs Interval/Dose 1 INH RIF EMB PZA 2 INH RIF EMB PZA Diagnosed Pulmonary TB 7 days/wk (56) or 5 days/wk (40) 7 days/wk (56) or 5 days/wk (40) INH/RIF 7 days/wk (126) or 5 days/wk (90) INH/RIF 3 days/wk (54) Effectiveness ATS/CDC/IDSA. AJRCCM :735
19 Alternative Regimens Initial Continuation Reg Drugs Interval/Dose Drugs Interval/Dose 3* INH RIF EMB PZA 4** INH RIF EMB PZA 3X wkly (24) INH/RIF 3X wkly (54) 7 days/wk (14) then twice wkly (12) INH/RIF 2X wkly (36) Effectiveness *Use with caution in patients with HIV or cavitary disease **Do not use in patients with HIV or smear positive and/or cavitary disease ATS/CDC/IDSA. AJRCCM :735
20 Treatment of Tuberculosis Completion of Therapy Completion of therapy is defined as the number of doses taken Initial phase - All of the specified doses should be delivered within 3 months Continuation phase - All of the specified doses should be administered within 6 months Thus, a 6-month regimen should be completed within 9 months ATS/CDC/IDSA AJRCCM 2016
21 Interruptions in Treatment Time point of interruption Details of interruption Approach Intensive Phase Lapse is < 14 days Continue treatment Continuation Phase Lapse is 14 days Received 80% of doses and was sm ( ) at diagnosis Received 80% of doses and was sm (+) at diagnosis Received < 80% of doses and lapse < 3 mos Restart treatment Received < 80% of doses and lapse 3 mos Further treatment may not be necessary Continue treatment unless 2 consecutive mos missed then restart Continue treatment Restart treatment
22 Treatment of Tuberculosis Extending Therapy in High Risk Isoniazid Rifampin Pyrazinamide Ethambutol Initial Continuation Phase* months *Extend continuation phase from 4 to 7 months if: 1) cavitary disease and 2) culture positive at 2 mos
23 Relapse Rates By Cavitation and 6 month regimen 2 Month Culture Status Cav+ C2m+ Cav+ C2m Cav C2m+ Cav C2m Daily Daily IP + thrice weekly CP Daily IP + twice weekly CP Thrice weekly Daily IP with Rp in CP Thrice weekly IP with Rp in CP IP intensive phase, CP continuation phase, Rp rifapentine Cav cavitary, C2m 2 month culture status Chang et al, AJRCCM 2006; 174;
24 Extending the Duration of Therapy Either cavitation or positive sputum culture at 2 months of therapy plus: >10 % below ideal body weight Smoker Diabetes mellitus HIV infection Other immunosuppressive conditions Extensive disease on chest radiograph
25 Case 1 29 year old HIV negative Chinese man with chronic cough, night sweats, and weight loss Sputum is AFB smear and culture positive After two months of treatment his smears are positive Culture results after two months of therapy return as negative
26 Audience Response Question This patient should be treated for 9 months. A. True B. False
27 Algorithm to Guide Duration of Continuation-Phase Treatment On anti-tb Rx No 2 month culture positive? Give continuationphase treatment for 4 months Yes Cavity present? No No HIVinfected? Yes Give continuationphase treatment for 7 months Yes CDC
28 Treatment in Special Situations Paucibacillary Disease (Sm, Cx ) 9. Does a shorter duration of treatment have similar outcomes compared to a standard 6 month treatment duration among HIV negative patients with paucibacillary TB? Suggest a 4-month treatment regimen for treatment of HIV-negative adult patients with AFB smear- and culture-negative pulmonary TB (Conditional recommendation / Very low quality of evidence) Study N Regimen Relapse Hong Kong 325 INH RIF PZA SM X 4 mos 4.0% Arkansas 414 INH RIF X 4 mos 1.2% Singapore 196 2INH RIF PZA / 2INH RIF 2INH RIF PZA / 2INH 3 RIF 3 <1.0%
29 Four-Month Regimen for Paucibacillary Disease On anti-tb Rx Initial culture negative? Yes 2 mos 4 mos Clinical or x-ray improved Yes No Give continuationphase treatment for 2 months Stop treatment
30 Monitoring for Treatment Response and Adverse Reactions Shaded - optional Nahid P, et al. Clin Infect Dis. 2016;63(7):e147-e195.
31 Management of Treatment Failure 90-95% of patients treated for pulmonary TB with regimens containing INH and RIF will have negative sputum cultures by 3 mos Treatment failure is defined as continuously or recurrently positive cultures after 4 mos If still culture positive after 3 months of therapy: Recheck drug susceptibility tests Assess adherence Consider malabsorption of drugs
32 Management of Treatment Failure Treatment failure - Culture positive after 4 months of therapy: If the patient is seriously ill or sputum AFB smear +, an empirical regimen should be started with at least 2-3 new drugs If the patient is not seriously ill consider waiting for the results of drug susceptibility testing
33 Randomized Trials of Short Course Flouroquinolone Regimens Study Location N Regimens ReMOX South Indian Trial OFLOTUB RIFAQUIN 9 countries in Africa, Asia, Central Am HRZE/4HR 2 HRZM/2HRM 2 MRZE/2MR 2 sites in India HRZE/4HR 2 HRZM/2HRM 2 HRZG/2HRG 5 countries in Africa 4 countries in Africa HRZE/4HR 2 HRZG/2HRG HRZE/4HR 2 RZEM/4M 1 Rp 1 2 RZEM/2M 2 Rp 2 Unfavorable Outcomes 16% 23% 24% 9% 11% 20% 17% 21% 14% 14% 27% P (in mitt analysis) NS NS NS NS S Gillespie SH, et al. NEJM 2014;371:1577 Jindani A et al. NEJM 2014;371:1599 Merle CS, et al NEJM 2014;371:1588 Jawahar MS, et al. PLoS One 2013;8 Lanoix JP, et al. Clin Infect Dis 2015
34 Summary Treatment and its completion is the single most important factor in controlling TB in a population Treatment involves initiation of 4 drugs in the initial phase followed by two drugs during the continuation phase Duration of therapy is 6 months Treatment should be extended to 9 months when cavitation is present on the x ray AND the culture is still positive after 2 month of therapy. Duration of therapy can be 4 months for smear and culture negative pulmonary TB Patients should be monitored for response to therapy (culture conversion) and for evidence of adverse drug reactions
Diagnosis and Treatment of Tuberculosis, 2011
Diagnosis of TB Diagnosis and Treatment of Tuberculosis, 2011 Alfred Lardizabal, MD NJMS Global Tuberculosis Institute Diagnosis of TB, 2011 Diagnosis follows Suspicion When should we Think TB? Who is
More informationTB Nurse Case Management San Antonio, Texas April 9-11, 2013
TB Nurse Case Management San Antonio, Texas April 9-11, 2013 TB / Dose Counting Rachel Munoz, RN. TB Nurse Case Manager/Nurse Consultant Austin/Travis County Health Department April 10, 2013 Rachel Munoz,
More informationTreatment of Tuberculosis
TB Clinical i l Intensive Seattle Treatment of Tuberculosis June 16, 2016 Masa Narita, MD Public Health Seattle & King County; Firland Northwest TB Center, University of Washington Outline Unique features
More information6/8/2018 TB TREATMENT. Bijan Ghassemieh, MD Seattle TB Clinical Intensive Disclosures. None
TB TREATMENT Bijan Ghassemieh, MD Seattle TB Clinical Intensive 2018 Disclosures None 1 Objectives Understand the following Rationale and goals for standard TB regimen When to initiate TB treatment Standard
More informationTuberculosis Intensive November 17 20, 2015 San Antonio, TX
Treatment of Tuberculosis Elizabeth S. Guy, MD November 17, 2015 Tuberculosis Intensive November 17 20, 2015 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Elizabeth S. Guy, MD has the following disclosures
More informationMoving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012
Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012 LTBI and TB Disease Treatment Cara Christ, MD, MS May 8, 2012 Cara Christ, MD, MS has the following disclosures to make: No conflict
More informationTreatment of Tuberculosis
Treatment of Tuberculosis Marcos Burgos, MD April 5, 2016 TB Intensive April 5 8, 2016 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Marcos Burgos, MD has the following disclosures to make: No conflict
More informationFundamentals of Tuberculosis (TB)
TB in the United States Fundamentals of Tuberculosis (TB) From 1953 to 1984, reported cases decreased by approximately 5.6% each year From 1985 to 1992, reported cases increased by 20% 25,313 cases reported
More informationTB Intensive San Antonio, Texas
TB Intensive San Antonio, Texas April 6-8, 2011 TB Disease: ATS/CDC/IDSA Guidelines Barbara Seaworth, MD Thursday April 7, 2011 Barbara Seaworth, MD has the following disclosures to make: Has received
More informationDiagnosis and Management of TB Disease Lisa Armitige, MD, PhD September 27, 2011
TB Nurse Case Management Davenport, Iowa September 27 28, 2011 Diagnosis and Management of TB Disease Lisa Armitige, MD, PhD September 27, 2011 Lisa Armitige, MD, PhD has the following disclosures to make:
More informationTreatment of Tuberculosis
Treatment of Tuberculosis, 1940 s Treatment of Tuberculosis ATS/CDC/IDSA Joint Statement 2003 Saskatchewan Lung Association Outline, 2012 Treatment of Tuberculosis Principles of treatment of tuberculosis
More informationDiagnosis and Medical Management of Latent TB Infection
Diagnosis and Medical Management of Latent TB Infection Marsha Majors, RN September 7, 2017 TB Contact Investigation 101 September 6 7, 2017 Little Rock, AR EXCELLENCE EXPERTISE INNOVATION Marsha Majors,
More informationTreatment of Tuberculosis
TB Intensive Tyler, Texas June 1-3, 2009 Treatment of Tuberculosis Barbara Seaworth, MD June 3, 2009 Treatment of Tuberculosis Barbara J Seaworth MD Medical Director Heartland National TB Center 1 Purpose
More informationTuberculosis and Diabetes Dec. 10, 2009 Dean Schillinger, M.D. and Gisela Schecter, M.D., M.P.H. 1 of 18
Screening, Diagnosis, and Treatment of TB in Persons with Diabetes Dean Schillinger, M.D. University of California San Francisco CA Diabetes Program Gisela Schecter, M.D., M.P.H. TB Control Branch CA Department
More informationTreatment of Active Tuberculosis
Treatment of Active Tuberculosis Jeremy Clain, MD Pulmonary & Critical Care Medicine Mayo Clinic October 16, 2017 2014 MFMER slide-1 Disclosures No relevant financial relationships No conflicts of interest
More informationTuberculosis Tools: A Clinical Update
Tuberculosis Tools: A Clinical Update CAPA Conference 2014 JoAnn Deasy, PA-C. MPH, DFAAPA jadeasy@sbcglobal.net Adjunct Faculty Touro PA Program Learning Objectives Outline the pathogenesis of active pulmonary
More informationRecognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016
Recognizing MDR-TB in Children Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention 17-18 February 2016 Objectives Review the definitions and categorization of drugresistant tuberculosis Understand the
More informationTB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012
TB: Management in an era of multiple drug resistance Bob Belknap M.D. Denver Public Health November 2012 Objectives: 1. Explain the steps for diagnosing latent and active TB role of interferon-gamma release
More information10/3/2017. Updates in Tuberculosis. Global Tuberculosis, WHO 2015 report. Objectives. Disclosures. I have nothing to disclose
Disclosures Updates in Tuberculosis I have nothing to disclose Chris Keh, MD Assistant Clinical Professor, Division of Infectious Diseases, UCSF TB Controller, TB Prevention and Control Program, Population
More informationContact Investigation and Prevention in the USA
Contact Investigation and Prevention in the USA George D. McSherry, MD Division of Infectious Disease Penn State Children s Hospital Pediatric Section TB Center of Excellence Rutgers Global Tuberculosis
More informationDIAGNOSIS AND MEDICAL MANAGEMENT OF TB DISEASE
DIAGNOSIS AND MEDICAL MANAGEMENT OF TB DISEASE Annie Kizilbash MD, MPH Assistant Professor University of Texas Health Science Center Staff Physician, Texas Center for Infectious Diseases TB Nurse Case
More informationCLINICAL DIAGNOSIS AND MANAGEMENT OF TB Disease
CLINICAL DIAGNOSIS AND MANAGEMENT OF TB Disease Barbara J Seaworth MD Medical Director Heartland National TB Center Professor of Medicine University of Texas Health Center Tyler Barbara J Seaworth MD has
More informationContact Investigation
Tuberculosis Ann Raftery, RN, PHN, MSc GHS Learning Objectives Upon completion of this session, participants will be able to: Describe the criteria used and method for determining the infectious period
More informationTherapeutic Drug Monitoring for Improving TB Treatment Outcomes: A Concept for a Randomized Clinical Trial before Clinical Implementation
Therapeutic Drug Monitoring for Improving TB Treatment Outcomes: A Concept for a Randomized Clinical Trial before Clinical Implementation Randall Reves, MD, MSc TB Consultant Professor of Medicine and
More informationTB in the Correctional Setting Florence, Arizona October 7, 2014
TB in the Correctional Setting Florence, Arizona October 7, 2014 Diagnosis and Treatment of TB Disease Renuka Khurana, MBBS, MPH October 7, 2014 Renuka Khurana, MSSB, MPH has the following disclosures
More informationThe treatment of patients with initial isoniazid resistance
The treatment of patients with initial isoniazid resistance 2011 INTERTB Meeting, St George s, London Patrick Phillips, MRC Clinical Trials Unit DA Mitchison, AJ Nunn. 21 st October 2011 Outline Background
More informationTreatment of Drug-Susceptible Tuberculosis
American Thoracic Society / Centers for Disease Control / Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis On behalf of the writing committee
More informationPre-Treatment Evaluation. Treatment of Latent TB Infection (LTBI) Initiating Treatment: Patient Education. Before initiating treatment for LTBI:
Pre-Treatment Evaluation Before initiating treatment for LTBI: Treatment of Latent TB Infection (LTBI) Amee Patrawalla, MD Associate Professor, New Jersey Medical School Attending Physician, NJMS Global
More informationhas the following disclosures to make:
CLINICAL DIAGNOSIS AND MANAGEMENT OF TB DISEASE Annie Kizilbash MD, MPH September 22, 2015 TB Nurse Case Management September 22 24, 2015 San Antonio. TX EXCELLENCE EXPERTISE INNOVATION Annie Kizilbash
More informationDiagnosis & Medical Case Management of TB Disease. Lisa Armitige, MD, PhD October 22, 2015
Diagnosis & Medical Case Management of TB Disease Lisa Armitige, MD, PhD October 22, 2015 Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS EXCELLENCE
More informationTB In Detroit 2011* Early TB: Smudge Sign. Who is at risk for exposure to or infection with TB? Who is at risk for TB after exposure or infection?
Those oral antibiotics are just not working! Inpatient Standards of Care & Discharge Planning S/He s in the Hospital: Now What Do I Do? Dana G. Kissner, MD TB Intensive Workshop, Lansing, MI 2012 Objectives:
More informationWhat you need to know about diagnosing and treating TB: a preventable, fatal disease. Bob Belknap M.D. Denver Public Health November 2014
What you need to know about diagnosing and treating TB: a preventable, fatal disease Bob Belknap M.D. Denver Public Health November 2014 The Critical First Step Consider TB in the Differential 1. Risks
More informationPediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017
Pediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has the following disclosures
More informationInvestigation of Contacts of Persons with Infectious Tuberculosis, 2005
1 Investigation of Contacts of Persons with Infectious Tuberculosis, 2005 Daniel P. Dohony, MPH Division of Tuberculosis Elimination Centers for Disease Control and Prevention and Philadelphia TB Control
More informationDose Counting Exercise Elizabeth Foy, RN, BSN September 8, 2016
Dose Counting Exercise Elizabeth Foy, RN, BSN September 8, 2016 TB Nurse Case Management September 7-9, 2016 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Jessica Quintero, M.Ed., has the following disclosures
More informationDrug Interactions Lisa Armitige, MD, PhD November 17, 2010
Substance Abuse and Tuberculosis Oklahoma City, Oklahoma November 17, 2010 Drug Interactions Lisa Armitige, MD, PhD November 17, 2010 Drug Interactions Lisa Y. Armitige, M.D., Ph.D. Medical Consultant
More informationNewer anti-tb drugs and regimens. DM Seminar
Newer anti-tb drugs and regimens DM Seminar 31-10-14 Why are newer drugs/regimens needed? Problems with current drugs/regimens Drug resistance Drug interaction of anti-tubercular drugs with ART Long duration
More informationINDEX CASE INFORMATION
Instructions for Completing the MDH Tuberculosis Contact Investigation Report Form Please provide as much information as possible. Each field represents information that is important to the contact investigation.
More informationMycobacterial Infections: What the Primary Provider Should Know about Tuberculosis
Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Epidemiology Diagnosis of active TB Screening
More informationTreatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015
Treatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015 Tuberculosis Infection Diagnosis and Treatment April 7, 2015 El Paso, TX EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has
More informationMarcos Burgos, MD has the following disclosures to make:
Guidelines for the Treatment of Tuberculosis Marcos Burgos, MD May 13, 2015 TB for Pulmonologist March 13, 2015 Phoenix, AZ EXCELLENCE EXPERTISE INNOVATION Marcos Burgos, MD has the following disclosures
More informationDisclosures. Updates in TB for the PCP: Opportunities for Prevention. Objectives PART 1: WHY TEST? 4/14/2016. None
Disclosures Updates in TB for the PCP: Opportunities for Prevention None Pennan Barry, MD, MPH Chief, Surveillance and Epidemiology, California TB Control Branch Assistant Clinical Professor, Division
More informationTB in the Patient with HIV
TB in the Patient with HIV Lisa Y. Armitige, MD, PhD May 11, 2017 TB Intensive May 9 12, 2017 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD, has the following disclosures to
More informationCHAPTER:1 TUBERCULOSIS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY
CHAPTER:1 TUBERCULOSIS BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY GLOBAL EMERGENCY: * Tuberculosis kills 5,000 people a day! * 2.3 million die each year!
More informationWhen Can Isolation Be Discontinued?
When Can Isolation Be Discontinued? - It Depends on the Patient and the Setting. Masae Kawamura M.D. and Barbara Seaworth M.D. Texas: (800) TEX-LUNG New Jersey: 973-972-3270? HNTC Consultation Line California:
More informationI. Demographic Information GENDER NUMBER OF CASES PERCENT OF CASES. Male % Female %
San Joaquin County (SJC) in 03, (N=43) County Rate = 6. Cases per 00,000 Population I. Demographic Information Table I-A: TB cases by gender, SJC, 03 (N=43) GENDER NUMBER OF CASES Male 6 60.5% Female 7
More informationThe Epidemiology of Tuberculosis in Minnesota,
The Epidemiology of Tuberculosis in Minnesota, 2011 2015 Minnesota Department of Health Tuberculosis Prevention and Control Program (651) 201-5414 Tuberculosis surveillance data for Minnesota are available
More informationTuberculosis 6/7/2018. Objectives. What is Tuberculosis?
Tuberculosis Understanding, Investigating, Eliminating Jeff Maupin, RN Tuberculosis Control Nurse Sedgwick County Division of Health Objectives At the conclusion of this presentation, you will be able
More informationTUBERCULOSIS. Pathogenesis and Transmission
TUBERCULOSIS Pathogenesis and Transmission TUBERCULOSIS Pathogenesis and Transmission Infection to Disease Diagnostic & Isolation Updates Treatment Updates Pathogenesis Droplet nuclei of 5µm or less are
More informationScott Lindquist MD MPH Tuberculosis Medical Consultant Washington State DOH and Kitsap County Health Officer
Tuberculosis in the 21 st Century Scott Lindquist MD MPH Tuberculosis Medical Consultant Washington State DOH and Kitsap County Health Officer Feedback Poll In my opinion, the recent media coverage of
More informationTBTC research update: are we ready for 3 month treatment? 2009 TBTC Recompetition. NTCA presentation outline
TBTC research update: are we ready for 3 month treatment? Stefan Goldberg, MD Project officer, TBTC Studies 27, 28, 29 Tuberculosis Trials Consortium (TBTC) CDC Division of TB Elimination NTCA breakout
More information5. HIV-positive individuals treated with INH should receive Pyridoxine (B6) 25 mg daily or 50 mg twice/thrice weekly on the same schedule as INH
V. TB and HIV/AIDS A. Standards of Treatment and Management The majority of TB treatment principles apply to persons with HIV/AIDS who require treatment for TB disease. The following points are either
More informationTuberculosis Populations at Risk
Tuberculosis Populations at Risk One-third of the world is infected with TB, an average of one new infection per second Two million people died from tuberculosis in 2010, 1 every 20 seconds TB is the leading
More informationErrors in Dx and Rx of TB
Errors in Dx and Rx of TB David Schlossberg, MD, FACP Professor of Medicine Temple University School of Medicine Medical Director, TB Control Program Philadelphia Department of Public Health TB Still a
More informationManagement of MDR TB. Dr Priscilla Rupali MD; DTM&H Professor and Head Department of Infectious Diseases Christian Medical College Vellore
Management of MDR TB Dr Priscilla Rupali MD; DTM&H Professor and Head Department of Infectious Diseases Christian Medical College Vellore Outline Global epidemiology of Tuberculosis Epidemiology of Tuberculosis
More informationPatient History 1. Patient History 2. Social History. The Role of Surgery in the Management of TB. Reynard McDonald, MD & Paul Bolanowski, MD
Patient History 1 The Role of Surgery in the Management of TB Reynard McDonald, MD & Paul Bolanowski, MD September 16, 2010 42 y/o AA male was initially diagnosed with pansensitive pulmonary TB in 1986
More informationDiagnosis and Medical Management of TB Disease. Quratulian Annie Kizilbash, MD, MPH March 17, 2015
Diagnosis and Medical Management of TB Disease Quratulian Annie Kizilbash, MD, MPH March 17, 2015 TB Nurse Case Management March 17 19, 2015 San Antonio, Texas EXCELLENCE EXPERTISE INNOVATION Quratulian
More informationMy heart is racing. Managing Complex Cases. Case 1. Case 1
Managing Complex Cases My heart is racing Amee Patrawalla, MD April 7, 2017 Case 1 Rutgers, The State University of New Jersey Rutgers, The State University of New Jersey Case 1 29 year old physician from
More informationTB and Comorbidities Adriana Vasquez, MD April 12, 2018
TB and Comorbidities Adriana Vasquez, MD April 12, 2018 TB Nurse Case Management April 10 12, 2018 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Adriana Vasquez, MD has the following disclosures to make:
More informationTUBERCULOSIS. Presented By: Public Health Madison & Dane County
TUBERCULOSIS Presented By: Public Health Madison & Dane County What is Tuberculosis? Tuberculosis, or TB, is a disease caused by a bacteria called Mycobacterium tuberculosis. The bacteria can attack any
More informationDiagnosis and Medical Management of TB Infection Lisa Y. Armitige, MD, PhD September 12, TB Nurse Case Management September 12 14, 2017
Diagnosis and Medical Management of TB Infection Lisa Y. Armitige, MD, PhD September 12, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has
More informationTUBERCULOSIS CONTACT INVESTIGATION
TB CASE MANAGEMENT AND CONTACT INVESTIGATION INTENSIVE TUBERCULOSIS CONTACT INVESTIGATION LEARNING OBJECTIVES Upon completion of this session, participants will be able to: 1. Describe the criteria used
More informationTitle: Meta-analysis of Individual patient Data (IPD) of Patients with INH (mono or poly-drug) Resistant Tuberculosis.
Title: Meta-analysis of Individual patient Data (IPD) of Patients with INH (mono or poly-drug) Resistant Tuberculosis. Principal Investigator: Dick Menzies, MD Evidence base for treatment of INH resistant
More informationNorthwestern Polytechnic University
Clinical Tuberculosis Assessment by Health Care Provider Clinicians should review and verify the information in the Tuberculosis (TB) Screening Questionnaire (attached). Persons answering YES to any questions
More informationTuberculosis Reporting, Waco-McLennan County Public Health District TB Control WMCPHD (254)
Tuberculosis Reporting, Waco-McLennan County Public Health District TB Control WMCPHD (254)-750-5496 Local health care providers, including physicians offices, labs and hospitals, are required by law to
More informationTB Intensive San Antonio, Texas December 1-3, 2010
TB Intensive San Antonio, Texas December 1-3, 2010 TB Case Presentations Doug Hornick, MD; Iowa U Medical School December 1, 2010 Pulmonary Fascinomas with a Tuberculous Attitude Douglas B. Hornick, MD
More informationTuberculosis (TB) Fundamentals for School Nurses
Tuberculosis (TB) Fundamentals for School Nurses June 9, 2015 Kristin Gall, RN, MSN/Pat Infield, RN-TB Program Manager Marsha Carlson, RN, BSN Two Rivers Public Health Department Nebraska Department of
More informationTreatment of Tuberculosis
Treatment of Tuberculosis American Thoracic Society, CDC, and Infectious Diseases Society of America Please note: An erratum has been published for this article. To view the erratum, please click here.
More informationHEALTH SERVICES POLICY & PROCEDURE MANUAL
PAGE 1 of 7 References Related ACA Standards 4 th Edition Standards for Adult Correctional Institutions 4-4350, 4-4355 These guidelines are based on the recommendations of the American Thoracic Society
More informationChapter 5 Treatment for Latent Tuberculosis Infection
Chapter 5 Treatment for Latent Tuberculosis Infection Table of Contents Chapter Objectives.... 109 Introduction.... 111 Candidates for the Treatment of LTBI... 112 LTBI Treatment Regimens.... 118 LTBI
More informationTOG The Way Forward
TOG 2016- The Way Forward Main Changes in Diagnostic algorithm Definition (Type, Classification, Outcome) Registration at the time of Diagnosis (PHI level Notification Register) Long term follow up (till
More informationHot Issues in Tuberculosis: Treatment of Latent TB Infection and New TB Drugs
Slide 1 Hot Issues in Tuberculosis: Treatment of Latent TB Infection and New TB Drugs Constance A. Benson, M.D. Professor of Medicine Division of Infectious Diseases University of California, San Diego
More informationTuberculosis: A Provider s Guide to
Tuberculosis: A Provider s Guide to Diagnosis and Treatment of Active Tuberculosis (TB) Disease and Screening and Treatment of Latent Tuberculosis Infection (LTBI) Alameda County Health Care Services Agency
More informationLatent TB, TB and the Role of the Health Department
Latent TB, TB and the Role of the Health Department Elaine Darnall, RN, BSN, CIC TB Nurse Consultant Illinois Dept of Public Health March 21, 2018 Elaine Darnall has disclosed that there is no actual or
More informationTB IN EMERGENCIES. Disease Control in Humanitarian Emergencies (DCE)
TB IN EMERGENCIES Department of Epidemic and Pandemic Alert and Response (EPR) Health Security and Environment Cluster (HSE) (Acknowledgements WHO Stop TB Programme WHO/STB) 1 Why TB? >33% of the global
More informationPlease distribute a copy of this information to each provider in your organization.
HEALTH ADVISORY TO: Physicians and other Healthcare Providers Please distribute a copy of this information to each provider in your organization. Questions regarding this information may be directed to
More informationTreatment of Tuberculosis
Recommendations and Reports June 20, 2003 / 52(RR11);1-77 Recommendations and Reports June 20, 2003 / 52(RR11);1-77 Treatment of Tuberculosis American Thoracic Society, CDC, and Infectious Diseases Society
More informationMycobacterium tuberculosis
Mycobacterium tuberculosis Mycobacterium tuberculosis Ø small, aerobic, nonmotile bacteria Ø Gram-positive bacillus Ø can survive in a dry state for weeks Ø grow only within the cells of a host organism
More informationThe Role of Rifampin for the Treatment of Latent TB Infection. Introduction. Introduction
The Role of Rifampin for the Treatment of Latent TB Infection March 26, 2008 Alfred A. Lardizabal, MD Associate Professor of Medicine New Jersey Medical School Global Tuberculosis institute Treatment of
More informationManaging the Patients Response to TB Treatment
Managing the Patients Response to TB Treatment Barbarah Martinez, RN, BSN September 13, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Barbarah Martinez, RN, BSN has
More informationEtiological Agent: Pulmonary Tuberculosis. Debra Mercer BSN, RN, RRT. Definition
Pulmonary Tuberculosis Debra Mercer BSN, RN, RRT Definition Tuberculosis is a contagious bacterial infection of the lungs caused by Mycobacterium Tuberculosis (TB) Etiological Agent: Mycobacterium Tuberculosis
More informationTB Classification (ATS/CDC)
bits and pieces Lisa Chen, MD UCSF Pulmonary/Critical Care Curry International Tuberculosis Center 10/2017 TB Classification (ATS/CDC) TB0 No tuberculosis exposure, not infected TB1 Tuberculosis exposure,
More informationTreatment of TB. David Griffith, MD May 12, TB for Community Providers. Phoenix, Arizona
Treatment of TB David Griffith, MD May 12, 2015 TB for Community Providers May 12, 2015 Phoenix, Arizona EXCELLENCE EXPERTISE INNOVATION David Griffith, MD has the following disclosures to make: No conflict
More informationTUBERCULOSIS CONTACT INVESTIGATION
TB CASE MANAGEMENT AND CONTACT INVESTIGATION INTENSIVE May 8-11, 2018 TUBERCULOSIS CONTACT INVESTIGATION LEARNING OBJECTIVES Upon completion of this session, participants will be able to: 1. Describe the
More informationTreatment of Tuberculosis Disease. Treatment of Tuberculosis. Decision to Treat Initiation of Therapy 1
Treatment of Tuberculosis Some Highlights of Most Recent Update Treatment of Tuberculosis Disease Germaine Jacquette, MD Physician Specialist NJMS Global Tuberculosis Institute September 15, 2010 The provider
More informationSummary Statistics of Reported and Verified Cases of Tuberculosis in San Joaquin County in 2012, (N=44) County Rate = 6.3 Cases per 100,000 Population
I. Demographic Information GENDER NUMBER OF CASES PERCENT OF CASES Male 29 65.9% Female 15 34.1% AGE GROUP NUMBER OF CASES PERCENT OF CASES 04 3 6.8% 514 2 4.5% 1524 3 6.8% 2544 6 13.6% 4564 15 34.1% 65+
More informationLet s Talk TB. A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year
A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Lancelot M. Pinto, MD, MSc Author Madhukar Pai, MD, PhD co-author and Series Editor Abstract Nearly 50% of patients with
More informationNew Drugs, New Treatments, Shorter Regimens
New Drugs, New Treatments, Shorter Regimens Sarah K. Brode, MD MPH FRCP(C) West Park Healthcare Centre, University Health Network, University of Toronto TB Elimination: Back to Basics November 16, 2016
More informationNEW DRUGS FOR TUBERCULOSIS: THE NEED, THE HOPE AND THE REALITY
NEW DRUGS FOR TUBERCULOSIS: THE NEED, THE HOPE AND THE REALITY Neil W. Schluger, M.D. Professor of Medicine, Epidemiology and Environmental Health Sciences Columbia University Global tuberculosis incidence
More informationPediatric TB Lisa Armitige, MD, PhD September 28, 2011
TB Nurse Case Management Davenport, Iowa September 27 28, 2011 Pediatric TB Lisa Armitige, MD, PhD September 28, 2011 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interest.
More informationDisclosures. Public Health Motivation 6/6/2012. The 12-Dose INH-Rifapentine Once-Weekly DOT Regimen: What Next?
The 12-Dose INH-Rifapentine Once-Weekly DOT Regimen: What Next? NTCA Conference June 14, 2012 John Jereb, FSEB, DTBE, CDC Special thanks to Christine Ho, Elsa Villarino, and Andrey Borisov The findings
More informationInternational Standards for Tuberculosis Care Barbara J. Seaworth, MD August 22, 2007
TB Along the US/Mexico Border El Paso, Texas August 22-23, 2007 International Standards for Tuberculosis Care Barbara J. Seaworth, MD August 22, 2007 Barbara J Seaworth MD Medical Director Heartland National
More informationTB in Corrections Phoenix, Arizona
TB in Corrections Phoenix, Arizona March 24, 2011 Treatment of Latent TB Infection Renuka Khurana MD, MPH March 24, 2011 Renuka Khurana, MD, MPH has the following disclosures to make: No conflict of interests
More informationTB is Global. Latent TB Infection (LTBI) Sharing the Care: Working Together. September 24, 2014
Sharing the Care: Working Together to Meet the Challenge of TB Presented by: Barbara Cole, RN, PHN, MSN Director, Disease Control County of Riverside Department of Public Health Curry International TB
More informationImproving Translation in TB Drug Development Through Quantitative Modeling. CPTR Workshop 2016, Washington DC
Improving Translation in TB Drug Development Through Quantitative Modeling Lessons from Recent Phase III TB Trials CPTR Workshop 2016, Washington DC Christian Lienhardt Global TB Programme WHO, Geneva,
More informationTB in Corrections Phoenix, Arizona
TB in Corrections Phoenix, Arizona March 24, 2011 Contact Investigation in the Correctional Setting Jessica Quintero, BAAS March 24, 2011 Jessica Quintero, BAAS has the following disclosures to make: No
More informationThe Elimination of Tuberculosis. Richard E. Chaisson, MD. Center for TB Research Center for AIDS Research Johns Hopkins University
The Elimination of Tuberculosis Richard E. Chaisson, MD Center for TB Research Center for AIDS Research Johns Hopkins University Disclosures Spouse owns Merck stock Consultant: Merck Research funding:
More informationTB ReFLECT Meta-Analysis of Fluoroquinolone-Containing Regimens for the Treatment of Drug-Susceptible TB
TB ReFLECT Meta-Analysis of Fluoroquinolone-Containing Regimens for the Treatment of Drug-Susceptible TB Rada Savic, PhD Medical Consultant Meeting San Antonio, TX November 29-30, 2018 1 EXCELLENCE EXPERTISE
More informationManaging Complex TB Cases Diana M. Nilsen, MD, RN
Managing Complex TB Cases Diana M. Nilsen, MD, RN Director of Medical Affairs NYC Department of Health & Mental Hygiene Bureau of TB Control Case #1 You are managing a patient who was seen at a private
More information